Beta Bionics insider sells $13,151 in stock

Mike Mensinger, an insider at the medical device company, reduces his stake by 0.56%

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mike Mensinger sold 1,064 shares of the company's stock on Monday, March 2nd. The shares were sold at an average price of $12.36, for a total transaction value of $13,151.04. Following the sale, Mensinger still directly owns 188,793 shares in the company, valued at approximately $2,333,481.48.

Why it matters

Insider transactions can provide insights into a company's performance and management's confidence in the business. Mensinger's sale, representing a 0.56% decrease in his position, may signal some uncertainty about Beta Bionics' near-term prospects, though his remaining substantial stake suggests he still believes in the company's long-term potential.

The details

The sale was disclosed in a filing with the Securities & Exchange Commission. Beta Bionics is a clinical-stage medical device company focused on automated insulin delivery solutions for people with type 1 diabetes. Its flagship product is the iLet Bionic Pancreas system, which is designed to simplify glycemic control by automatically adjusting insulin dosing.

  • The shares were sold on Monday, March 2nd.
  • Mensinger also sold 2,200 shares on Tuesday, January 6th and 7,800 shares on Friday, January 2nd.

The players

Mike Mensinger

An insider at Beta Bionics, Inc. who directly owns 188,793 shares in the company.

Beta Bionics, Inc.

A clinical-stage medical device company headquartered in Boston, Massachusetts, focused on automated insulin delivery solutions for people with type 1 diabetes.

Got photos? Submit your photos here. ›

What they’re saying

“This trade represents a 0.56% decrease in their position.”

— Mike Mensinger, Insider (SEC filing)

The takeaway

Insider transactions can provide valuable insights into a company's performance and management's confidence. While Mensinger's sale represents a small reduction in his stake, his remaining substantial ownership suggests he still believes in Beta Bionics' long-term potential as it develops its innovative automated insulin delivery solutions.